Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia

Cancer

Volumn 117, Issue 22, 2011, Pages 5074-5084

  Guidetti, Anna ^a   Carlo Stella, Carmelo ^a,b   Ruella, Marco ^c   Miceli, Rosalba ^a   Devizzi, Lilli ^a   Locatelli, Silvia L ^a,b   Giacomini, Arianna ^a,b   Testi, Adele ^a   Buttiglieri, Stefano ^c   Risso, Alessandra ^c   Mariani, Luigi ^a   Di Nicola, Massimo ^a   Passera, Roberto ^d   Tarella, Corrado ^c   Gianni, Alessandro M ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d MOLINETTE HOSPITAL   (Italy)

Author keywords

high dose radioimmunotherapy; non Hodgkin lymphoma; secondary myelodysplastic syndrome and acute myelogenous leukemia; telomere length; yttrium 90 ibritumomab tiuxetan

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; IBRITUMOMAB TIUXETAN; PLATINUM DERIVATIVE; RITUXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; AUTOGRAFT; CANCER INCIDENCE; CANCER RISK; CELL COUNT; CHROMOSOME SIZE; COHORT ANALYSIS; COLONY FORMING UNIT GM; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MEGADOSE; ERYTHROID PRECURSOR CELL; FEMALE; FIBROBLAST; FOLLOW UP; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOTOPE LABELING; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOIMMUNOTHERAPY; RISK ASSESSMENT; RISK FACTOR; SINGLE DRUG DOSE; TELOMERE; THERAPY EFFECT; TIME SERIES ANALYSIS; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BONE MARROW; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE PROGENITOR CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; RADIOIMMUNOTHERAPY; RISK; TELOMERE; YTTRIUM RADIOISOTOPES;

EID: 80053045567     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26182     Document Type: Article

References (45)

1. Wrench D, Gribben JG,. Stem cell transplantation for non-Hodgkin's lymphoma. Hematol Oncol Clin North Am. 2008; 22: 1051-1079, xi.
2. Tarella C, Zanni M, Magni M, et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei Linfomi survey. J Clin Oncol. 2008; 26: 3166-3175.
3. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997; 336: 1290-1297. (Pubitemid 27187782)
4. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood. 2004; 103: 4429-4431. (Pubitemid 38745967)
5. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002; 20: 3262-3269. (Pubitemid 34831524)
6. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003; 21: 1263-1270. (Pubitemid 46606402)
7. Gisselbrecht C, Bethge W, Duarte RF, et al. Current status and future perspectives for yttrium-90 ([90]Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant. 2007; 40: 1007-1017. (Pubitemid 350147685)
8. Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2008; 26: 90-95.
9. Palanca-Wessels MC, Press OW,. Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas. Cancer. 2010; 116: 1126-1133.
10. Park SI, Press OW,. Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies. Curr Opin Hematol. 2007; 14: 632-638. (Pubitemid 47494079)
11. Nademanee A, Forman S, Molina A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood. 2005; 106: 2896-2902. (Pubitemid 41510771)
12. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood. 2003; 102: 2351-2357. (Pubitemid 37193569)
13. Ferrucci PF, Vanazzi A, Grana CM, et al. High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas. Br J Haematol. 2007; 139: 590-599. (Pubitemid 350043818)
14. Devizzi L, Guidetti A, Tarella C, et al. High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol. 2008; 26: 5175-5182.
15. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S,. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003; 21: 897-906. (Pubitemid 46613489)
16. Stone RM, Neuberg D, Soiffer R, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1994; 12: 2535-2542. (Pubitemid 24379636)
17. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000; 95: 1588-1593. (Pubitemid 30120817)
18. Pedersen-Bjergaard J, Andersen MK, Christiansen DH,. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood. 2000; 95: 3273-3279. (Pubitemid 30428453)
19. Lenz G, Dreyling M, Schiegnitz E, et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol. 2004; 22: 4926-4933. (Pubitemid 46638617)
20. Kalaycio M, Rybicki L, Pohlman B, et al. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol. 2006; 24: 3604-3610. (Pubitemid 46630533)
21. Miller JS, Arthur DC, Litz CE, Neglia JP, Miller WJ, Weisdorf DJ,. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood. 1994; 83: 3780-3786. (Pubitemid 24175569)
22. Tarella C, Passera R, Magni M, et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol. 2011; 29: 814-824.
23. Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007; 25: 4285-4292. (Pubitemid 47548569)
24. Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005; 105: 4576-4582. (Pubitemid 40807274)
25. Greenberger JS,. Toxic effects on the hematopoietic microenvironment. Exp Hematol. 1991; 19: 1101-1109.
26. Soligo DA, Lambertenghi Deliliers G, Servida F, et al. Haematopoietic abnormalities after autologous stem cell transplantation in lymphoma patients. Bone Marrow Transplant. 1998; 21: 15-22. (Pubitemid 28043431)
27. Domenech J, Linassier C, Gihana E, et al. Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation. Blood. 1995; 85: 3320-3327.
28. Rocci A, Ricca I, Dellacasa C, et al. Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir. Exp Hematol. 2007; 35: 673-681. (Pubitemid 46427960)
29. Akiyama M, Asai O, Kuraishi Y, et al. Shortening of telomeres in recipients of both autologous and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2000; 25: 441-447. (Pubitemid 30114040)
30. Ricca I, Compagno M, Ladetto M, et al. Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following 2 tightly spaced high-dose chemotherapy courses with G-CSF. Leukemia. 2005; 19: 644-651. (Pubitemid 40521170)
31. Ruella M, Rocci A, Ricca I, et al. Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status. Bone Marrow Transplant. 2010; 45: 505-512.
32. Bhatia R, Van Heijzen K, Palmer A, et al. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma. J Clin Oncol. 2005; 23: 6699-6711. (Pubitemid 46190265)
33. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329: 987-994.
34. Magni M, Di Nicola M, Testi A, et al. Radioimmunotherapy and secondary leukemia: a case report [serial online]. Leuk Res. 2010; 34: e1-e4.
35. Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood. 2003; 102: 749-755. (Pubitemid 36842002)
36. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114: 937-951.
37. Cilloni D, Carlo-Stella C, Falzetti F, et al. Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation. Blood. 2000; 96: 3637-3643.
38. Tarella C, Passera R, Magni M, et al. Male gender, quality of grafted cells, advanced age, rituximab and radiotherapy are the main factors that variously influence the occurrence of secondary malignancies following high-dose therapy and autograft: a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) survey in 1347 lymphoma patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114. Abstract 519.
39. Gray RJ,. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Anal Stat. 1988; 16: 1141-1154.
40. Forrest DL, Hogge DE, Nevill TJ, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J Clin Oncol. 2005; 23: 7994-8002. (Pubitemid 46657400)
41. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003; 102: 43-52. (Pubitemid 36759634)
42. Betticher DC, Huxol H, Muller R, Speck B, Nissen C,. Colony growth in cultures from bone marrow and peripheral blood after curative treatment for leukemia and severe aplastic anemia. Exp Hematol. 1993; 21: 1517-1521. (Pubitemid 24216790)
43. Hong SS, Karayan L, Tournier J, Curiel DT, Boulanger PA,. Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J. 1997; 16: 2294-2306. (Pubitemid 27258631)
44. Unryn BM, Hao D, Gluck S, Riabowol KT,. Acceleration of telomere loss by chemotherapy is greater in older patients with locally advanced head and neck cancer. Clin Cancer Res. 2006; 12: 6345-6350. (Pubitemid 44799703)
45. Chakraborty S, Sun CL, Francisco L, et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol. 2009; 27: 791-798.